Titan Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Titan Pharmaceuticals has a total shareholder equity of $6.6M and total debt of $500.0K, which brings its debt-to-equity ratio to 7.5%. Its total assets and total liabilities are $8.1M and $1.4M respectively.
Key information
7.5%
Debt to equity ratio
US$500.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.76m |
| Equity | US$6.64m |
| Total liabilities | US$1.44m |
| Total assets | US$8.09m |
Recent financial health updates
Recent updates
Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?
Jul 10
Titan Pharma regains Nasdaq listing compliance
Dec 16Titan Pharmaceuticals announces 1-for-30 reverse stock split
Nov 30Titan Pharmaceuticals EPS misses by $0.01, beats on revenue
Nov 16Titan Pharma closes debt settlement and JT-09 acquisition
Nov 02Titan Pharma to raise $8M in stock offering
Oct 28Financial Position Analysis
Short Term Liabilities: TTNP's short term assets ($8.0M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: TTNP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: TTNP has more cash than its total debt.
Reducing Debt: TTNP's debt to equity ratio has reduced from 63.2% to 7.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TTNP has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: TTNP is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.